August 15, 2024
Our lab has received a new grant from the Department of Defense to support our work on uveal melanoma! We are excited to share new findings in this still not well-studied cancer.
August 13, 2024
Apoorva Upreti joins for Rotation. Welcome!
August 4, 2024
Read our latest review on NK cells and its success in cancer therapy.
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1456631/full
July 9, 2024
Our lab identifies new inhibitor that promotes ant-tumor effects in RAS-driven cancer in Journal of Translational Medicine. Very interesting finding- Learn more about this work-
https://pubmed.ncbi.nlm.nih.gov/38982514/
June 26, 2024
Our lab has published new research demonstrating the important role of ASAH1 and ceramide metabolism in triple-negative breast cancer (TNBC) in Cell Death & Disease and Molecular Metabolism – Read more on this work-
https://pubmed.ncbi.nlm.nih.gov/38926346/
https://pubmed.ncbi.nlm.nih.gov/38599378/
June 1, 2024
Lab receives new grant from the NCI/NIH to support our research work on breast cancer! This support will help advance our work on TNBC.
May 14, 2024
Dr. Gupta has received the Dean’s Excellence Award in Research. This achievement is a testament to our team’s collective hard work, dedication, and collaboration. A big thank you to everyone on our team!
https://www.uab.edu/medicine/news/latest/item/3036-2024-deans-excellence-awards
April 23, 2024
We are excited to share our latest research in iScience, which explores the use of an ALK inhibitor in combination with anti-PD-1 therapy and ABT-263 for treating hepatocellular carcinoma (HCC).
https://pubmed.ncbi.nlm.nih.gov/38741708/
November 21, 2023
We are happy to share our new work on pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancers published in Cell Reports Medicine-
Great work team!
https://pubmed.ncbi.nlm.nih.gov/37951219/
July 6, 2023
Our newly published work in Cell Death & Disease identifies ATAD2 as promoter of ovarian cancer growth and metastasis. Read more on this work-
https://pubmed.ncbi.nlm.nih.gov/37479754/
June 6, 2023
Kevin Graciano joined the lab as PREP scholar. He will be working on discovering new therapy for melanoma patients. Welcome!
March 15, 2023
Teresa B. Chiyanne joined the lab for Ph.D. thesis. She will be working on breast cancer therapy resistance, one of the biggest challenges in the area of breast cancer therapy. Welcome!
January 15, 2023
Amber R. Johnson and Maria Fernanda Salcedo Noriega joined us as Rotating Graduate Students. Welcome!
November 2, 2022
Our newly published work in NAR Cancer identifies UBE2T as promoter of breast cancer growth. Excellent work, Congratulations to the team!
https://pubmed.ncbi.nlm.nih.gov/36338541/
August 15, 2022
Teresa C. Beamon and Tyler Freeland joined us as Rotating Graduate Students. Welcome!
June 17, 2022
We are happy to share our new work in melanoma published in iScience- Great work team!
https://pubmed.ncbi.nlm.nih.gov/35942091/
June 17, 2022
See our new published article in Frontiers in Oncology about new and advanced approach for identification of new targets and mechanisms driving drug resistance in melanoma. Congratulations to the team!
https://pubmed.ncbi.nlm.nih.gov/35785205/
March 2, 2022
Read our new published review in American Journal of Cell-Physiology about regulation and targeting of ECM for cancer therapy.
https://pubmed.ncbi.nlm.nih.gov/35235427/
February 3, 2022
In our new published review in Trends in Cancer, we provide an overview of the transcriptional mechanisms that drive the response and resistance to immunotherapies. We also discuss possible interventions to enhance the outcomes of immunotherapies by targeting dysregulated transcriptional networks in cancer cells.
https://pubmed.ncbi.nlm.nih.gov/35125331/
January 11, 2022
Congratulations to Dr. Gupta for receiving the highly prestigious UAB Pittman’s Scholars award
https://www.uab.edu/medicine/news/latest/item/2476-2022-pittman-scholars
October 26, 2021
We are thrilled to share our new work identifying TP-472 as a potentially useful therapeutic agent for melanoma therapy published in Cancers journal.
https://www.mdpi.com/2072-6694/13/21/5516
September 16, 2021
Epigenetic factors drive drug resistance and have direct implications for the prevention and treatment of drug-resistant cancer. To know more, read our new review published in Cancer Research journal.
https://pubmed.ncbi.nlm.nih.gov/34531319/
July 20, 2021
Lab receives prestigious, five-year $1.63 million R01 grant from the NCI/NIH to support our research work on breast cancer!
July 12, 2021
Congratulations to the team for the excellent study published in Oncogenesis journal showing the role of epigenetic modifier DOT1L in ovarian cancer. Our study was widely covered at various science news sites and was one of the most-read articles!
https://pubmed.ncbi.nlm.nih.gov/34253709/
https://www.uab.edu/news/research/item/12197-ovarian-cancer-potential-therapeutic-target-identified
https://www.sciencedaily.com/releases/2021/08/210805154731.htm
June 7, 2021
Dr. Kiran K. Reddi joined as Postdoc. Welcome!
May 17, 2021
Dr. Praveen Guruvaiah joined as Postdoc. Welcome!
October 6, 2020
Read our informative review on Transcriptional regulators and alterations that drive melanoma initiation and progression published in Oncogene journal.
https://pubmed.ncbi.nlm.nih.gov/33024276/
July 7, 2020
Dr. Jasvinder Singh joined as Postdoc. Welcome!
September 1, 2020
We are grateful to receive funding from Department of Defense (DoD) FY19 Idea Award with Special Focus to support our research work!
August 28, 2020
Our collaborative study with Wajapeyee lab identifies LIMK2 to be an important driver of Triple Negative breast cancer. This study was published in Oncogenesis journal.
https://pubmed.ncbi.nlm.nih.gov/32859889/
August 17, 2020
Lawrence D. Mason joined us as a Rotating Graduate Student. Welcome!
July 7, 2020
Dr. Roshan Dutta joined as Postdoc. Welcome!
June 8, 2020
Our study Identifying Mutational Landscape of Gynecological Malignancies published in Journal of Cancer.
https://pubmed.ncbi.nlm.nih.gov/32626534/
June 2, 2020
Read our important finding published in PNAS in the area of pancreatic cancer
https://pubmed.ncbi.nlm.nih.gov/32430335/
May 20, 2020
Our work revealing the loss of HAT1 confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R published is online at Oncogenesis journal.
https://pubmed.ncbi.nlm.nih.gov/32371878/
March 2, 2020
We are grateful to get the funding from NIH Small Grant Program (R03) for our work on Ovarian Cancer.
November 4, 2019
Stephanie Cooper joined us as a Rotating Graduate Student. Welcome!
September 1, 2019
Dr. Deepmala Shrestha joined as Postdoc. Welcome!
June 15, 2019
The Gupta Lab opens at the University of Alabama at Birmingham!
